The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Aeterna Zentaris

Monday Biotech Deal Review: January 30, 2012

Welcome to your Monday Biotech Deal Review for January 30, 2012.  Juicy news from last week include the $15M bought-deal that Oncolytics entered into with a syndicate of underwriters, as well as the closing of other private placement financings.  Read on to learn more. 

Monday Biotech Deal Review: January 9, 2012

Happy New Year and welcome back to your Monday Biotech Deal Review for January 9, 2012, following a holiday hiatus.  Link below to our review of transactions that have occurred over the previous three weeks.  Noteworthy transactions include various acquisitions by Valeant as well as a refinancing of its existing debt facilities.   Read on to learn [...]

Monday Biotech Deal Review: November 28, 2011

Welcome to your Monday Biotech Deal Review for November 28, 2011.  Notable events from the previous week include the announcement of a fully-subscribed brokered private placement by Resverlogix for proceeds of $17.5 million, as well as the announcement by Valeant of an agreement to acquire iNova (Valeant’s appetite for acquisitions continues, unabated), a prescription and OTC seller and [...]

Monday Biotech Deal Review: July 11, 2011

Welcome to your Monday Biotech Deal Review for July 11, 2011.  This week is a double feature, owing to last week’s break due to both Canada Day and Fourth of July holidays.  There was a lot of activity over the past two weeks in the biotech space.   Read on to catch up! 

Monday Biotech Deal Review: March 7, 2011

Welcome to your Monday Biotech Deal Review for March 7, 2011.  It was a busy week with numerous private and public investments, offerings by biotech companies (see Stem Cell Therapeutics and Adherex Technologies), as well as some interesting licensing activity.  Read on to learn more. 

Monday Biotech Deal Review: February 28, 2011

Welcome to your Monday biotech deal review for February 28, 2011.  In addition to the usual reviews of biotech corporate activity, this week featured the announcement of Theratechnologies’ U.S. IPO, the closing of a $40M bought deal by Paladin Labs, Angiotech’s recapitalization amendment and the appointment of a Receiver for LAB Research.  Read on to [...]

Monday Biotech Deal Review: January 31, 2011

Welcome to your Monday Biotech Deal Review for January 31, 2011.  Angiotech has voluntarily entered into CCAA proceedings and will continue its restructuring efforts there.  There was also some investment activity involving government agencies in Ontario, Quebec and Prince Edward Island.  Read on to learn more, as well as the usual assortment of biotech news [...]

Monday Biotech Deal Review: August 9, 2010

Catching up from the long weekend last week, we have a full two weeks’ worth of deals to bring you. Highlights include $16.7 million of securities closings, $8.25 million launched; and interesting developments in the Forbes Medi-Tech and Northstar Healthcare acquisitions. Check out what the last two weeks have wrought…

Monday Biotech Deal Review: July 19, 2010

Lots of deals this week. Some good news, some bad news. On the good news front, a steady volume of securities and M&A activity is continuing through the summer; and one Canadian firm benefits from the U.S. Defense Departments exploration of RNAi products as anti-virals. On the other hand front, though, a licensing option expired, a liquidation proceeded [...]

Monday Biotech Deal Review: July 5, 2010

Not a bad week for deals, considering the holiday weekend in both Canada and the U.S.. Response Biomedical placed a PIPE with OrbiMed funds, CTI did a follow-on round in Zymeworks and LAB Research took an equity line. Plus a companion diagnostic deal from Aeterna, just as I’m planning for Diagnostics Asia in August. The week’s [...]

Monday Biotech Deal Review: June 28, 2010

We follow a number of trends here at the blog, and two of them showed up as Canadian deals this week. Add those to the Biovail-Valeant merger, Æterna’s offering and a whole slew of commercial deals, and it’s been a pretty big week in Canadian deal-making.

Monday Biotech Deal Review: June 21, 2010

This week saw a slew of licensing and commercial deals, including HIV programs for MedMira in Nigeria and Dignitas in Malawi. On the securities side, Aquinox’s $25 million B round headlined a $47 million week. Rounding out the week is Enerkem’s demonstration project funding, which will go towards reducing emissions from biorefineries.

Monday Biotech Deal Review: May 3, 2010

I guess the excitement of BIO was driving deals this week. To the delight of the economic development folks, government was in on the action — Ontario announced a BIP investment and announced a whole new strategy, and OICR funded three equity deals. The private sector was also out in force, with four new licensing deals [...]

Monday Biotech Deal Review: April 26, 2010

This week’s deals are highlighted by a new TSX-V listed biotech, a $16 million D round, five collaborations a FedDev win for Bioniche, and updates on this month’s flurry of financings.

Monday Biotech Deal Review: April 19, 2010

This week’s deals are headlined by Æterna Zentaris’ $15 million placement (on the back of positive regulatory news over the last couple of weeks). Æterna Zentaris’ is joined by a passel of other private placements, but not much else.  As a bonus for a slow deal week, though, we’ll throw in a name change and [...]

Monday Biotech Deal Review: February 1, 2010

Canadian biotech companies were busy making and closing deals this week, with $44 million raised, four new licensing and collaboration deals, and particularly big weeks for Ospens and the MDS/Dahaner transaction.

Monday Biotech Deal Review: January 25, 2010

Everyone’s looking to the future in this week’s deal review: two special committees, 225,000 options, two royalty streams, a delisting notice and the first income trust/tax loss deal of 2010. 

Monday Biotech Deal Review: December 21, 2009

This week’s deal review shows no signs of a holiday showdown.  In Canada, BioMS’ deal with Spectral Diagnostics was interesting as a possible indicator of more to come and internationally, 5 new pharma deals were announced this morning including a $430 million deal that OncoGenex landed from Teva joining new links between Athersys and Pfizer, Lilly and Incyte, sanofi-aventis [...]

Monday Biotech Deal Review: October 25, 2009

A very busy deal week coincided with a very busy work week (for those of us with day jobs), so allow me a particularly grateful thank-you to Jacob Cawker, who’s been an invaluable help with the Deal Review this and the last several weeks.  After the jump, licenses both inbound, outbound and just tied up (optioned); securities extended and [...]

Monday Deal Review: June 29, 2009

This week’s Monday Deal Review has a full set of equity deals from shelf to launch to close, one new U.S. registration and one deregistration to match, and some ideas for what to do with your debt (!), all

Monday Deal Review: June 22, 2009

A whole gaggle of securities deals, a cluster of licenses and a flock of M&A all migrate back to Canada for summer in this week’s Monday Deal Review.  Plus, a deal that may improve the medical isotope shortage.  

Monday Deal Review: June 15, 2009

Another active week for Canadian deals, headed by Merck’s new deal with Xenon, along with some new funding, some new collaborations, and some new products coming to, and going from, Canadian companies all for your easy-reading pleasure

Monday Deal Review: May 4, 2009

Canadian deal and company news this week: Big drama at Patheon’s AGM, a public offering (!), some collaboration news and a completed private placement.

Monday Deal Review: March 9, 2009

A big dose of Canadian deals and company info from this week

Follow

Get every new post delivered to your Inbox.

Join 84 other followers